Form 4: MeiraGTx CFO & COO Richard Giroux Reports Share Vesting

MeiraGTx Holdings plc's CFO and COO, Richard Giroux, reported the vesting of 60,000 restricted share units and the subsequent disposition of 31,726 shares for tax purposes.

Summary

• Richard Giroux, CFO & COO of MeiraGTx Holdings plc, acquired 60,000 ordinary shares on February 21, 2026, due to the vesting of restricted share units.
• These shares represent one-quarter of the restricted share units granted on February 21, 2023.
• Concurrently, 31,726 ordinary shares were disposed of at a price of $7.45 per share to cover tax liabilities associated with the vesting event.
• Following these transactions, Mr. Giroux directly beneficially owns 1,027,530 ordinary shares.
• Additionally, Mr. Giroux indirectly beneficially owns 5,152 ordinary shares through his spouse and 85,000 ordinary shares through Aigle Healthcare Partners III LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a standard executive compensation vesting and tax withholding, with the executive maintaining a substantial equity stake.

Positives

• The vesting of 60,000 restricted share units indicates a scheduled compensation event for a key executive.
• Richard Giroux continues to hold a significant number of shares (over 1 million directly), aligning his interests with shareholders.

Negatives

• 31,726 ordinary shares were sold to cover tax obligations, representing a reduction in direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting and tax-related sales are common in the biotechnology sector, particularly for executives in growth-oriented companies like MeiraGTx. These transactions typically reflect pre-scheduled compensation plans rather than discretionary trading based on new company developments.

Comparison to Industry Standards

• StockSavvy.ai observes that the executive's continued substantial direct and indirect shareholdings, totaling over 1.1 million shares, are consistent with strong insider alignment seen in successful biotech firms. For instance, executives at comparable gene therapy companies often maintain significant equity stakes, reinforcing confidence in long-term value creation.
• The tax-related sale is a standard practice and does not indicate a lack of confidence, similar to how executives at companies like Sarepta Therapeutics or Bluebird Bio manage their equity compensation.

Stakeholder Impact

• Shareholders: The executive's continued significant shareholding aligns interests with shareholders. The tax-related sale is a minor dilution event but is standard practice.
• Employees: This is a compensation event for a specific executive, not broadly impacting all employees.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted share units and a subsequent tax-related share disposition. Such transactions are generally pre-scheduled and do not typically signal a change in the company's fundamental outlook or the executive's confidence. The executive maintains a substantial equity position, which is a positive for shareholder alignment. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

MeiraGTx Holdings plc, MGTX, Richard Giroux, CFO, COO, SEC Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Share Ownership, Executive Compensation, Biotechnology, Gene Therapy